Effects of imatinib mesylate on Renin-Angiotensin System (RAS) activity during the clinical course of chronic myeloid leukaemia

Journal of International Medical Research

Volumn 37, Issue 4, 2009, Pages 1018-1028

  Sayitoglu, M ^a   Haznedaroǧlu, Ibrahim C ^b   Hatirnaz, O ^a   Erbilgin, Y ^a   Aksu, S ^b   Koca, E ^b   Adiguzel, C ^c   Bayik, M ^d   Akalin, I ^c   Gulbas Z ^e   Akay, M ^e   Unal, A ^f   Kaynar, L ^f   Ovali, E ^g   Yilmaz, M ^g   Yenerel, M ^h   Dagdas, S ⁱ   Ozet, G ⁱ   Ar, C ^j   Aydin, Y ^j   Soysal, T ^j   Durgun, B ^k   Ozcebe, O ^b   Tukun, A ^l   Ilhan, O ^l   Ozbek, U ^a   more..

^a ISTANBUL UNIVERSITY   (Turkey)

^b HACETTEPE UNIVERSITY   (Turkey)

^c MARMARA UNIVERSITY   (Turkey)

^d Istanbul School of Medicine   (Turkey)

^e OSMANGAZI UNIVERSITY MEDICAL FACULTY   (Turkey)

^f ERCIYES UNIVERSITY MEDICAL FACULTY   (Turkey)

^g KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^h ISTANBUL UNIVERSITY   (Turkey)

ⁱ ANKARA NUMUNE HOSPITAL   (Turkey)

^j ISTANBUL UNIVERSITY   (Turkey)

^k Medical Department   (Turkey)

^l ANKARA UNIVERSITY   (Turkey)

more..

Author keywords

Angiotensin Converting Enzyme (ACE); Angiotensinogen; Chronic myeloid leukaemia, Renin Angiotensin System (RAS); Imatinib mesylate therapy; Renin; Tyrosine kinase inhibitors

Indexed keywords

ANGIOTENSINOGEN; ANTHRACYCLINE; CYTARABINE; DIPEPTIDYL CARBOXYPEPTIDASE; HEMOGLOBIN; IDARUBICIN; IMATINIB; MESSENGER RNA; RENIN; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DISEASE COURSE; FEMALE; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SPLENOMEGALY; THROMBOCYTE COUNT; ADOLESCENT; BONE MARROW; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECT; GENE EXPRESSION; GENETICS; METABOLISM; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANGIOTENSINOGEN; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; DRUG THERAPY, COMBINATION; FEMALE; GENE EXPRESSION; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; MALE; MIDDLE AGED; PEPTIDYL-DIPEPTIDASE A; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; RENIN; RENIN-ANGIOTENSIN SYSTEM; YOUNG ADULT;

EID: 70350494257     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700406     Document Type: Article

References (41)

1. Haznedaroǧlu IC, Tuncer S, Gürsoy M: A local renin-angiotensin system in the bone marrow. Med Hypotheses 1996; 46: 507-510. (Pubitemid 26184769)
2. Haznedaroǧlu IC: A local renin-angiotensin system in the bone marrow still awaits its Christopher Columbus. Exp Hematol 1998; 26: 279.
3. Haznedaroǧlu IC: A local renin-angiotensin system in the bone marrow: hypothesis and clues. Exp Hematol 1999; 27: 186-187.
4. Haznedaroǧlu IC, Büyükasik Y: Current evidence for the existence of a local renin-angiotensin system affecting physiological and pathological haemopoiesis in the bone marrow. Br J Haematol 1997; 99: 471.
5. Haznedaroǧlu IC, Oztürk MA: Towards the understanding of the local hematopoietic bone marrow renin-angiotensin system. Int J Biochem Cell Biol 2003; 35: 867-880. (Pubitemid 36379328)
6. Zambidis ET, Park TS, Yu W, et al: Expression of angiotensin-converting enzyme (CD143) identifies and regulates primitive hemangioblasts derived from human pluripotent stem cells. Blood 2008; 112: 3601-3614.
7. Jokubaitis VJ, Sinka L, Driessen R, et al: Angiotensin-converting enzyme (CD143) marks hematopoietic stem cells in human embryonic, fetal, and adult hematopoietic tissues. Blood 2008; 111: 4055-4063.
8. Acar K, Beyazit Y, Sucak A, et al: Alterations in the 'local umbilical cord blood renin- angiotensin system' during pre-eclampsia. Acta Obstet Gynecol Scand 2007; 86: 1193-1199. (Pubitemid 47463713)
9. Goker H, Haznedaroǧlu IC, Beyazit Y, et al: Local umbilical cord blood renin-angiotensin system. Ann Hematol 2005; 84: 277-281. (Pubitemid 41166820)
10. Oztürk MA, Güven GS, Haznedaroǧlu IC: How hematopoietic stem cells know and act in cardiac microenvironment for stem cell plasticity? Impact of local renin-angiotensin systems. Med Hypotheses 2004; 63: 866-874.
11. Akalin I, Koca E, Karabulut HG, et al: Angiotensin-converting enzyme (ACE) insertion/deletion (I/D) gene polymorphisms in leukemic hematopoiesis. Eur J Human Genet 2007; 15(suppl 1): 161.
12. Aksu S, Beyazit Y, Haznedaroglu IC, et al: Enhanced expression of the local haematopoietic bone marrow renin-angiotensin system in polycythemia rubra vera. J Int Med Res 2005; 33: 661-667. (Pubitemid 43009593)
13. Aksu S, Beyazit Y, Haznedaroǧlu IC, et al: Overexpression of angiotensin-converting enzyme (CD 143) on leukemic blasts as a clue for the activated local bone marrow RAS in AML. Leuk Lymphoma 2006; 47: 891-896. (Pubitemid 43840646)
14. Beyazit Y, Aksu S, Haznedaroǧlu IC, et al: Overexpression of the local bone marrow renin-angiotensin system in acute myeloid leukemia. J Natl Med Assoc 2007; 99: 57-63. (Pubitemid 46183959)
15. Koca E, Haznedaroǧlu IC, Uner A, et al: Angiotensin-converting enzyme expression of the lymphoma-associated macrophages in the lymph nodes of Hodgkin's disease. J Natl Med Assoc 2007; 99: 1243-1244, 1246-1247. (Pubitemid 350246906)
16. Koca E, Haznedaroǧlu IC, Acar K, et al: Renin-angiotensin system expression in the K562 human erythroleukaemic cell line. J Renin Angiotensin Aldosterone Syst 2007; 8: 145-147. (Pubitemid 350148452)
17. + hematopoietic cells. Cancer Res 2006; 66: 6628-6637.
18. Haznedaroǧlu IC, Arici M, Büyükaşik Y: A unifying hypothesis for the renin-angiotensin system and hematopoiesis: sticking the pieces together with the JAK-STAT pathway. Med Hypotheses 2000; 54: 80-83.
19. Vrsalovic MM, Pejsa V, Veic TS, et al: Bone marrow renin-angiotensin system expression in polycythemia vera and essential thrombocythemia depends on JAK2 mutational status. Cancer Biol Ther 2007; 6: 1434-1436. (Pubitemid 351590354)
20. Kerkelä R, Grazette L, Yacobi R, et al: Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nat Med 2006; 12: 908-916. (Pubitemid 44175142)
21. Baccarani M, Castagnetti F, Simonsson B, et al: Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): results of an European leukemianet prospective study comparing 400 mg and 800 mg front-line. Blood (ASH Annual Meeting Abstracts) 2008; 112: abstract 185.
22. Rosti G, Martinelli G, Baccarani M: In reply to 'Cardiotoxicity of the cancer therapeutic agent imatinib mesylate'. Nat Med 2007; 13: 15; author reply 15-16.
23. Haznedaroǧlu I, Tokgözoǧlu L, Caǧlar M, et al: Local cardiac renin-angiotensin system and hypertensive heart disease. Hypertension 1994; 24: 816-818. (Pubitemid 24363984)
24. Sokal JE, Cox EB, Baccarani M, et al: Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood 1984; 63: 789-799.
25. Bonifazi F, De Vivo A, Rosti G, et al (Italian Cooperative Study Group on Chronic Myeloid Leukaemia): Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with á-interferon. Br J Haematol 2000; 111: 587-595.
26. Vandesompele J, De Preter K, Pattyn F, et al: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002; 3: research0034.1 - research0034.11.
27. Pfaffl MW, Horgan GW, Dempfle L: Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 2002; 30: e36.
28. Hayran M, Koca E, Haznedaroǧlu IC, et al: Predicting chronic leukaemias from assessment of complete peripheral blood counts. J Int Med Res 2006; 34: 640-647. (Pubitemid 46165388)
29. Ager EI, Neo J, Christophi C: The renin-angiotensin system and malignancy. Carcinogenesis 2008; 29: 1675-1684.
30. Force T, Krause DS, Van Etten RA: Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-344. (Pubitemid 46652481)
31. + chronic myeloid leukemia (CML) patients. Blood (ASH Annual Meeting Abstracts) 2007; 110: abstract 26.
32. Rosti G, Martinelli G, Castagnetti F, et al: Imatinib 800 mg: preliminary results of a phase II trial of the GIMEMA CML working party in intermediate Sokal risk patients and status-of-the-art of an ongoing multinational, prospective randomized trial of imatinib standard dose (400 mg daily) vs high dose (800 mg daily) in high Sokal risk patients. Blood (ASH Annual Meeting Abstracts) 2005; 106: abstract 1098.
33. Koca E, Cetiner D, Goker H, et al: Complete cytogenetic remission with imatinib mesylate treatment in chronic myelogenous leukemia (CML) developed after renal transplantation. Clin Nephrol 2005; 64: 324-326. (Pubitemid 41448439)
34. Schellings MW, Baumann M, van Leeuwen RE, et al: Imatinib attenuates end-organ damage in hypertensive homozygous TGR(mRen2)27 rats. Hypertension 2006; 47: 467-474. (Pubitemid 43740292)
35. Kelly DJ, Cox AJ, Gow RM, et al: Platelet-derived growth factor receptor transactivation mediates the trophic effects of angiotensin II in vivo. Hypertension 2004; 44: 195-202.
36. Yoshiji H, Kuriyama S, Noguchi R, et al: Amelioration of liver fibrogenesis by dual inhibition of PDGF and TGF-β with a combination of imatinib mesylate and ACE inhibitor in rats. Int J Mol Med 2006; 17: 899-904.
37. Patterson KC, Weissmann A, Ahmadi T, et al: Imatinib mesylate in the treatment of refractory idiopathic pulmonary arterial hypertension. Ann Intern Med 2006; 145: 152-153. (Pubitemid 46780594)
38. Fazel S, Cimini M, Chen L, et al: Cardioprotective c-kit+ cells are from the bone marrow and regulate the myocardial balance of angiogenic cytokines. J Clin Invest 2006; 116: 1865-1877. (Pubitemid 44033311)
39. Yin G, Yan C, Berk BC: Angiotensin II signaling pathways mediated by tyrosine kinases. Int J Biochem Cell Biol 2003; 35: 780-783. (Pubitemid 36379319)
40. Iliescu C, Yusuf SW, Auerbach L, et al: Impact of angiotensin converting enzyme inhibitors and carvedilol on recovery of cardiac function in imatinib associated cardiomyopathy. J Card Fail 2005; 11(No.6 suppl): S104.
41. Fukuda D, Sata M: Role of bone marrow renin-angiotensin system in the pathogenesis of atherosclerosis. Pharmacol Ther 2008; 118: 268-276.